Get notified when VERA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVera Therapeutics names Nancy Bowman Chief Regulatory Officer, effective August 3
Filed July 9, 2026 · Period ending July 9, 2026 · ~1 min read
Key Changes
-
medium
Nancy Bowman, M.D., Ph.D. appointed Chief Regulatory Officer effective August 3, 2026, succeeding William Turner who transitions to Special Advisor for Regulatory Affairs.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (UNF 10-Q) is open in full — no account needed.
Partner
Trade VERA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 9, 2026 · How we verify